.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma crease, occupying the best scientific research area at Sanofi.Quigley
Read moreSanofi spends $110M upfront for late-stage radioligand therapy
.Sanofi has created a late access to the radioligand event, paying 100 thousand euros ($ 110 thousand) in advance for international rights to a neuroendocrine
Read moreSanofi flunks MS study, giving one more strike to Denali pact
.Sanofi has ceased a period 2 difficulty of Denali Therapeutics-partnered oditrasertib in a number of sclerosis. The French drugmaker tore the RIPK1 prevention hardship from
Read moreSangamo slashes opportunity to market for Fabry genetics treatment as FDA accepts sped up confirmation package deal
.Sangamo Therapeutics has recognized a shortcut to market for its own Fabry disease prospect, straightening with the FDA on a pathway that can reduce three
Read moreSage gives up fifty percent of R&D staff and shocks C-suite once more
.Sage Therapies’ latest attempt to reduce its pipe and also staff will definitely see a third of the biotech’s workers going to the exits alongside
Read moreRoivant introduces new ‘vant’ to progress Bayer hypertension med
.Matt Gline is back with a brand-new ‘vant’ company, after the Roivant Sciences CEO spent Bayer $14 thousand beforehand for the civil rights to a
Read moreRoche wagers around $1B to grow Dyno genetics therapy delivery contract
.After developing a gene treatment relationship along with Dyno Rehabs in 2020, Roche is actually back for more.In a new package possibly worth more than
Read moreRoche tosses out $120M tau possibility, coming back rights to UCB
.Roche has actually come back the civil rights to UCB’s anti-tau antibody bepranemab, ignoring a $120 thousand bank on the Alzheimer’s disease drug prospect on
Read moreRoche is keeping out hopes that its own injectable excessive weight prospect could eventually demonstrate 25% weight reduction in late-stage test
.Roche is actually storing out chances that its own injectable obesity possibility might at some point show 25% fat loss in late-stage trials, the pharma’s
Read moreRoche culls hack prospect, turns KRAS system in Q3 upgrade
.Roche’s severe cough program has faltered to a standstill. The drugmaker, which axed the plan after the medicine candidate disappointed in stage 2, disclosed (PDF)
Read more